AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CHIMERIC THERAPEUTICS LTD

0.011

+0.00222.22%

Volume:2.03M

Turnover:22.25K

Market Cap:892.01K

PE:-0.01

High:0.011

Open:0.009

Low:0.009

Close:0.009

52wk High:0.400

52wk Low:0.009

Shares:81.09M

Float Shares:29.07M

Volume Ratio:0.70

T/O Rate:7.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.758

EPS(LYR):-0.772

ROE:-1290.99%

ROA:-26.96%

PB:-0.29

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Chimeric Therapeutics Posts Prelim Loss for Year of A$18.8 MLN

Chimeric Therapeutics - no Dividends Paid or Declared for Year Ended June 30, 2026

THOMSON REUTERS

Chimeric Therapeutics - Prelim Loss for the Year A$18.8 Mln

THOMSON REUTERS

Chimeric Therapeutics Ltd - Major Cost Reductions Implemented, Expected to Reduce Annualised Expenditure by Around A$4 Mln

THOMSON REUTERS

Chimeric Therapeutics Ltd - Intends to Enter Negotiations with Its Creditors

THOMSON REUTERS

Chimeric Therapeutics Ltd - FY26 Financial Report Expected to Include a Material Uncertainty in Relation to Going Concern

THOMSON REUTERS

Chimeric Therapeutics - Conducted Process to Explore Potential to Sell, Out Licence or Partner Chm Cdh17 Asset and Programme

THOMSON REUTERS

Chimeric Therapeutics Ltd - Intends to Re-Engage with Potential Partners as in Vivo Pathway Advances

THOMSON REUTERS

Chimeric Therapeutics Seeks Trading Halt

Chimeric Therapeutics - Securities Placed in Trading Halt Pending Announcement on Results of Cdh17 Clinical Trial

THOMSON REUTERS

Chimeric Therapeutics Ltd-final Director's Interest Notice

THOMSON REUTERS

BUZZ-Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial

Chimeric Therapeutics Ltd-Chm Announces Positive Phase 1/2 Data at Asco

THOMSON REUTERS

Insider Buyers At Chimeric Therapeutics Likely Disappointed With 18% Slide

Simply Wall St.

Notification regarding unquoted securities - CHM-CHM

Capital Consolidation Complete-CHM

Chimeric Therapeutics Ltd-Update - Consolidation/Split - Chm-Chm

THOMSON REUTERS

Update - Consolidation/Split - CHM-CHM

Chimeric Therapeutics reports 100% manufacturing, release success for CDH17 autologous CAR-T program

Chimeric Therapeutics Ltd-Update - Consolidation/Split - Chm

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/CHM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.011,"timestamp":1788156720000,"preClose":0.009,"halted":0,"volume":2033701,"delay":0,"changeRate":0.22222222222222224,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":29070766,"shares":81091613,"eps":-0.758007,"marketStatus":"Not Yet Opened","change":0.002,"latestTime":"08-31 16:12:00 AEST","open":0.009,"high":0.011,"low":0.009,"amount":22249,"amplitude":0.222222,"askPrice":0.012,"askSize":468018,"bidPrice":0.011,"bidSize":87236,"shortable":3,"etf":0,"ttmEps":-0.758007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.009,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.7042227721092322,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CHM.AU","preClose":0.009,"auctionPrice":0.009,"auctionVolume":17,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156000739}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":29070766,"roa":"-26.96%","roe":"-1290.99%","lyrEps":-0.771524,"volumeRatio":0.7042227721092322,"shares":81091613,"dividePrice":0,"high":0.011,"amplitude":0.222222,"preClose":0.009,"low":0.009,"week52Low":0.009,"pbRate":"-0.29","psRate":"0.09","week52High":0.4,"institutionHeld":0,"latestPrice":0.011,"committee":-0.68578,"eps":-0.758007,"divideRate":0,"volume":2033701,"delay":0,"ttmEps":-0.758007,"open":0.009,"prevYearClose":0.2,"prevWeekClose":0.009,"prevMonthClose":0.011,"prevQuarterClose":0.065,"fiveDayClose":0.015,"twentyDayClose":0.042,"sixtyDayClose":0.082,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-04-22","symbol":"CHM.AU","defaultRemindTime":1776816000000,"type":"split","dateTimestamp":1776780000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663074219","title":"Chimeric Therapeutics Posts Prelim Loss for Year of A$18.8 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074219","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074219?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:31","pubTimestamp":1788172309,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLNAug 31 (Reuters)-Chimeric Therapeutics LtdCHM.AX:PRELIM LOSS FOR THE YEAR A$18.8 MILLIONNO DIVIDENDS PAID OR DECLARED FOR YEAR ENDED JUNE 30, 2026Further company coverage:CHM.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663781960","title":"Chimeric Therapeutics - no Dividends Paid or Declared for Year Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663781960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663781960?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:37","pubTimestamp":1788161869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R07B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078156","title":"Chimeric Therapeutics - Prelim Loss for the Year A$18.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663078156?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:37","pubTimestamp":1788161869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490216","title":"Chimeric Therapeutics Ltd - Major Cost Reductions Implemented, Expected to Reduce Annualised Expenditure by Around A$4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490216?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:09","pubTimestamp":1787094560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F16D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490215","title":"Chimeric Therapeutics Ltd - Intends to Enter Negotiations with Its Creditors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490215?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:09","pubTimestamp":1787094560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660349021","title":"Chimeric Therapeutics Ltd - FY26 Financial Report Expected to Include a Material Uncertainty in Relation to Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2660349021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660349021?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:09","pubTimestamp":1787094560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F16D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660270490","title":"Chimeric Therapeutics - Conducted Process to Explore Potential to Sell, Out Licence or Partner Chm Cdh17 Asset and Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2660270490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660270490?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:09","pubTimestamp":1787094560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F16D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660205490","title":"Chimeric Therapeutics Ltd - Intends to Re-Engage with Potential Partners as in Vivo Pathway Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660205490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660205490?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:09","pubTimestamp":1787094560,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F16D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103789","title":"Chimeric Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103789?lang=en_us&edition=fundamental","pubTime":"2026-08-17 07:55","pubTimestamp":1786924534,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Seeks Trading HaltAug 17 (Reuters)-Chimeric Therapeutics LtdCHM.AX:SECURITIES PLACED IN TRADING HALT PENDING ANNOUNCEMENT ON RESULTS OF CDH17 CLINICAL TRIALFurther company coverage:CHM.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nFWN44C03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103207","title":"Chimeric Therapeutics - Securities Placed in Trading Halt Pending Announcement on Results of Cdh17 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103207?lang=en_us&edition=fundamental","pubTime":"2026-08-17 07:54","pubTimestamp":1786924477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260816:nFWN44C03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649067956","title":"Chimeric Therapeutics Ltd-final Director's Interest Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2649067956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649067956?lang=en_us&edition=fundamental","pubTime":"2026-07-07 12:41","pubTimestamp":1783399289,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUE5V8HZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640073980","title":"BUZZ-Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640073980","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640073980?lang=en_us&edition=fundamental","pubTime":"2026-06-01 12:16","pubTimestamp":1780287382,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial** Shares of Australia's Chimeric Therapeutics CHM.AX rise as much as 40% to A$0.14, marking their biggest intraday pct gain since April 27 ** Stock hits its highest level since May 15** The clinical stage cell therapy company announces positive Phase 1/2 data for its CHM CDH17 clinical trial ** The Phase 1/2 trial is two-stage study designed to determine recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours** Company says current update reflects additional patients treated, the commencement of Dose Level 3, translational data and longer follow-up** About 582,942 shares change hands, 3.3x the 30-day average ** Stock down 42.5%, YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nL4N42909V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640986224","title":"Chimeric Therapeutics Ltd-Chm Announces Positive Phase 1/2 Data at Asco","url":"https://stock-news.laohu8.com/highlight/detail?id=2640986224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640986224?lang=en_us&edition=fundamental","pubTime":"2026-06-01 06:27","pubTimestamp":1780266458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nTUE9LV0FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634485684","title":"Insider Buyers At Chimeric Therapeutics Likely Disappointed With 18% Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2634485684","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634485684?lang=en_us&edition=fundamental","pubTime":"2026-05-10 06:03","pubTimestamp":1778364212,"startTime":"0","endTime":"0","summary":"Insiders who acquired AU$3.01m worth of Chimeric Therapeutics Limited's ( ASX:CHM ) stock at an average price of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-chm/chimeric-therapeutics-shares/news/insider-buyers-at-chimeric-therapeutics-likely-disappointed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-chm/chimeric-therapeutics-shares/news/insider-buyers-at-chimeric-therapeutics-likely-disappointed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","CHM.AU","BK7067","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631749045","title":"Notification regarding unquoted securities - CHM-CHM","url":"https://stock-news.laohu8.com/highlight/detail?id=2631749045","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631749045?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:25","pubTimestamp":1777512341,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nASX3PZBsT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nASX3k5FWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530218","title":"Capital Consolidation Complete-CHM","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530218?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:30","pubTimestamp":1777419025,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260428:nASX6PyQhy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nASX1M3G3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537741","title":"Chimeric Therapeutics Ltd-Update - Consolidation/Split - Chm-Chm","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631537741?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:23","pubTimestamp":1777418606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUEHFLKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631530491","title":"Update - Consolidation/Split - CHM-CHM","url":"https://stock-news.laohu8.com/highlight/detail?id=2631530491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631530491?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:23","pubTimestamp":1777418606,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260428:nASX3Qd3TZ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nASX7CqlNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629205036","title":"Chimeric Therapeutics reports 100% manufacturing, release success for CDH17 autologous CAR-T program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629205036","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629205036?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:04","pubTimestamp":1776773046,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics reported a 100% batch manufacturing and release success rate for its CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal cancers.Minaris supported clinical supply at about one autologous batch per month over past five years.Manufacturing cadence planned to expand to two batches per month, subject to patient enrollment and trial requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chimeric Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2Tvx2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628229888","title":"Chimeric Therapeutics Ltd-Update - Consolidation/Split - Chm","url":"https://stock-news.laohu8.com/highlight/detail?id=2628229888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628229888?lang=en_us&edition=fundamental","pubTime":"2026-04-17 10:34","pubTimestamp":1776393253,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUE8TJBZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}